National Pain Report—August 4, 2017
In an article by National Pain Report, HSS rheumatologist Sergio Schwartzman, MD commented on the Arthritis Advisory Committee of the FDA’s recent decision to not recommend the drug sirukumab for the treatment of rheumatoid arthritis. The drug was created as an alternative treatment for adults with RA who had inadequate or intolerant responses to other available treatments. According to the article, sirukumab was not approved due to the safety data.
"The availability of alternative treatment options, including a new molecular entity like sirukumab, is critically important in my ability as a practicing rheumatologist to help patients control their disease, especially considering the complexity and heterogeneity of an autoimmune disease like rheumatoid arthritis," said Dr. Schwartzman. He added that he hopes the FDA will carefully consider the current need for additional rheumatoid arthritis treatment options on behalf of patients and practicing rheumatologists.
Read the full article at nationalpainreport.com